Oncosoft
Latest round
- Series B
Last raised
- Sep 2024
Total raised
- $10M
Investors
- 8
About Oncosoft
Founded in 2019 by Kim Jin-sung (CEO), and based in Seoul, South Korea, Oncosoft Inc. is a medical software provider that uses AI-based technology on a cloud service platform to provide radiotherapy and radiology services primarily to hospitals and medical applications in order to diagnose cancerous cells. In July 2026, Oncosoft Inc. The firm offers software used in the radiotherapy part of cancer treatment that uses artificial intelligence to provide accurate, fully automated segregations of samples. Additionally, the software offers a contouring studio that draw samples from simple to complex organs to perform image segmentation by using traditional, regional, and deformable registration algorithms.
Who invested in Oncosoft
8 investors across 3 rounds
See all investors in Oncosoft
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Oncosoft
Who invested in Oncosoft?
Oncosoft has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Oncosoft raised?
Oncosoft has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Oncosoft last raise money?
Oncosoft's most recent round on record is a Series B, in Sep 2024.
What does Oncosoft do?
Founded in 2019 by Kim Jin-sung (CEO), and based in Seoul, South Korea, Oncosoft Inc.
Where is Oncosoft headquartered?
Oncosoft is headquartered in Seoul, South Korea.
Which VCs invest in companies like Oncosoft?
Among active investors with capital left to deploy, Yufu Capital, ICBC Capital Management, Ningbo Tongshang Fund and Boc Private Equity Firm back software companies at Oncosoft's stage. Their profiles are linked below.
VCs backing software startups at Series B
Raising like Oncosoft? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.